Search
Close this search box.

A Step-by-Step Guide to Performance Evaluation for IVD Devices by Operon Strategist

Performance evaluation is a crucial step in the development and validation of in vitro diagnostic (IVD) devices. It ensures that...

BD, a global medical technology company, has recently announced its expansion of access to advanced image-enabled, spectral cell sorters. This...

Greenlight Guru Clinical is a leading provider of quality management software for the medical technology industry. Their platform offers a...

Greenlight Guru, a leading provider of quality management software specifically designed for the medical device industry, has once again proven...

Managing budgets and meeting milestones are crucial aspects of conducting successful clinical investigations in the field of medical technology (MedTech)....

The National Medical Products Administration (NMPA) in China has been busy in April 2024, with several important updates and developments...

The Food and Drug Administration (FDA) has recently announced that it will be clearing the use of Bluetooth technology in...

The Food and Drug Administration (FDA) has recently announced that it will be clearing Bluetooth medical devices for use in...

The National Medical Products Administration (NMPA) recently issued a new guideline aimed at improving usability engineering in medical devices. This...

The National Medical Products Administration (NMPA) in China recently issued a new guideline for usability engineering in medical devices. This...

As the global healthcare industry continues to expand, medical device manufacturers are increasingly looking to explore international markets to tap...

As the global healthcare industry continues to expand, medical device manufacturers are increasingly looking to explore international markets for growth...

Sequana Medical, a leading medical device company focused on the development of innovative solutions for the management of fluid overload...

Introduction ISO 13485:2016 and Part 820.25 are two important standards that govern the quality management systems of medical device manufacturers....

Healthcare cloud computing has revolutionized the way medical devices are managed and operated in the healthcare industry. By utilizing cloud-based...

BioCardia, a leading biotechnology company focused on the development of innovative regenerative therapies for cardiovascular diseases, has recently received a...

ElectroCore, a leading bioelectronic medicine company, has recently been awarded a grant to further develop a groundbreaking treatment for post-traumatic...

The Food and Drug Administration (FDA) plays a crucial role in ensuring the safety and efficacy of medical products in...

Drug-device combination products are becoming increasingly popular in the healthcare industry, offering a unique approach to treating various medical conditions....

Haryana, one of India’s leading states in terms of industrial development, has recently announced its ambitious Medical Device Manufacturing Policy...

Colorectal cancer is a type of cancer that starts in the colon or rectum, and it is the third most...

Drug-device combination products have become increasingly popular in the healthcare industry, offering a unique approach to treating various medical conditions....

Vapotherm, a leading global medical technology company, is set to introduce its latest innovation, the Access365 Home Ventilation Solution, at...

Medtronic, a global leader in medical technology, recently announced a strategic shift in its approach to ventilators in response to...

Health Canada plays a crucial role in ensuring the safety and effectiveness of medical devices in Canada. One important aspect...

Health Canada plays a crucial role in ensuring the safety and effectiveness of medical devices in Canada. One important aspect...

Sysmex Corporation, a leading global healthcare company, has been making waves in the field of robotics with its innovative approach...

Starting April 1, RF Aesthetic Equipment will need a Device Certificate As of April 1, 2022, all Radio Frequency (RF)...

Genesis MedTech, a leading medical technology company, has recently announced a partnership with Silk Road Medical to improve healthcare access...

Genesis MedTech, a leading medical technology company, has recently announced a partnership with Silk Road Medical to improve healthcare access...

Comparison of Afrezza® with MDI and Insulin Pumps in INHALE-3 Study’s Initial Meal Challenge Results

The INHALE-3 study, a groundbreaking clinical trial comparing the efficacy of Afrezza® with traditional insulin delivery methods, has recently released its initial meal challenge results. Afrezza® is a rapid-acting inhaled insulin that offers a convenient and discreet alternative to traditional insulin injections. The study aimed to evaluate how Afrezza® performs in comparison to multiple daily injections (MDI) and insulin pumps in managing blood sugar levels after a meal.

The results of the initial meal challenge in the INHALE-3 study have shown promising outcomes for Afrezza® users. Participants who used Afrezza® experienced significantly lower postprandial glucose levels compared to those using MDI or insulin pumps. This indicates that Afrezza® may be more effective in controlling blood sugar spikes after meals, which is crucial for individuals with diabetes to prevent long-term complications.

One of the key advantages of Afrezza® is its rapid onset of action, which allows for quicker absorption of insulin into the bloodstream. This can help mimic the body’s natural insulin response to food intake, leading to better glucose control. In contrast, traditional insulin injections and pumps may have a slower onset of action, resulting in delayed effects on blood sugar levels.

Another important finding from the INHALE-3 study is the convenience and ease of use of Afrezza® compared to MDI and insulin pumps. Afrezza® is inhaled through a small handheld device, eliminating the need for needles and syringes. This can be particularly beneficial for individuals who have a fear of needles or struggle with the complexity of insulin pump therapy.

Despite these positive results, it is important to note that Afrezza® may not be suitable for everyone with diabetes. Individuals with certain respiratory conditions or allergies to insulin should consult with their healthcare provider before considering Afrezza® as a treatment option. Additionally, further research is needed to fully understand the long-term effects and safety profile of Afrezza® compared to traditional insulin delivery methods.

In conclusion, the initial meal challenge results from the INHALE-3 study suggest that Afrezza® may offer a promising alternative to MDI and insulin pumps for managing blood sugar levels after meals. Its rapid onset of action, convenience, and potential for improved glucose control make it an attractive option for individuals with diabetes. However, more research is needed to confirm these findings and determine the optimal use of Afrezza® in clinical practice.